Introduzca una acción o criptomoneda en el cuadro de búsqueda para obtener un resumen
SkinBioTherapeutics PLC
SBTXSkinBioTherapeutics plc, a life science company, engages in identification and development of technology that harnesses the human microbiome to improve health in the United Kingdom, the United States, and Europe. It develops SkinBiotix technology that promotes skin health by harnessing the beneficial properties of probiotic bacteria and the active components; and AxisBiotix technology that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis. The company has an agreement with Croda Plc; and operates two research programmes with the University of Manchester, an oral programme and an inflammation study. It serves cosmetic skincare, food supplements, medical skin care, infection control, and pharmaceutical skincare markets. The company was formerly known as Skinbiotix Ltd and changed its name to SkinBioTherapeutics plc in December 2016. SkinBioTherapeutics plc was incorporated in 2015 and is based in Newcastle upon Tyne, the United Kingdom. Address: The Core, Newcastle upon Tyne, United Kingdom, NE4 5TF
Analytics
Precio Objetivo de WallStreet
3 625.36 GBXRelación P/E
–Rentabilidad por dividendo
–Año en curso
Año anterior
Trimestre actual
Último trimestre
Año en curso
Año anterior
Trimestre actual
Último trimestre
Cifras clave SBTX
Análisis de dividendos SBTX
Aumento del dividendo durante 5 años
–Crecimiento continuo
–Ratio de pago medio en 5 años
–Tendencia del payout SBTX
Valoración de la acción SBTX
Finanzas SBTX
Realice un seguimiento de las métricas clave de cada acción en un solo lugar y sin complicaciones
Hazte premiumResultados | 2019 | Dinámica |